Related Experiment Videos
Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy
Bernardo Liberato1, Adrienne Riethmuller, Raymond L Comenzo
1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Journal of Neuro-Oncology
|June 27, 2003
Abstract:
Approximately 20% of patients with Waldenström's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.